Repligen Q2 GAAP EPS drops 65.38% to $0.09; revenue rises 12% to $204 million
RGEN•Second-quarter results
- Repligen Q2 revenue rose 12% year over year to $204 million; GAAP EPS fell to $0.09.
- GAAP operating income was $14 million, up 1% year over year; adjusted operating income climbed 55% to $34 million.
- Adjusted diluted EPS increased 46% to $0.54; GAAP gross margin widened 2.9 percentage points to 53.9%.
Updated full-year guidance
- Raised FY2026 guidance to revenue of $813 million-$835 million, adjusted EPS of $2.03-$2.09.
Acquisition and expansion update
- Signed a definitive agreement to acquire BioLife Solutions; opened a Repligen Training & Innovation Center in Breda, Netherlands.
